Methotrexate Viatris (Methotrexate Sodium)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This interruption reduces the synthesis of nucleotides needed for DNA and RNA production, thereby limiting the proliferation of fast‑growing cells such as immune cells in autoimmune disease and cancer cells in malignancies.

The specific dose of Methotrexate Viatris is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosing regimens vary widely across indications, and the prescriber will tailor the amount and frequency to achieve optimal therapeutic effect while minimizing risk.

Methotrexate Viatris is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk and may harm the infant.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Methotrexate is an antimetabolite, whereas many other immunosuppressants, such as biologic agents, target specific cytokines or cell surface receptors. Methotrexate offers a broad‑acting mechanism that can be effective for both autoimmune diseases and certain cancers, but it may have a different side‑effect profile, including more frequent hepatic and hematologic monitoring.

Methotrexate Viatris, supplied as a subcutaneous injectable, should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial, as these conditions could compromise stability and potency.

Methotrexate Viatris is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient following aseptic technique. The exact site, volume, and frequency are prescribed by the treating physician based on the indication.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute renal failure, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, lung function, renal parameters, and blood counts to detect these complications early.

Methotrexate Viatris should be avoided in pregnant women, individuals with severe renal or hepatic impairment, patients with uncontrolled infections, and those who have had hypersensitivity reactions to methotrexate or any of its excipients. Clinicians must also assess contraindications such as recent live‑vaccine administration.